EIF4EBP1 and acute lymphoblastic leukemia: Treatment of B-ALL cells with SBI-756 in the 250–500 nM range strongly reduced formation of the eIF4F complex in cells without impacting mTORC1 signaling outputs (pS6, p4E-BP1).